enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. Why VIVUS Lost in November - AOL

   www.aol.com/news/2012-12-04-why-vivus-lost-in...

   VIVUS' (NAS: VVUS) stock was down 25% for November, though still up 15% for the year. Its drug Qsymia is the first obesity drug to be approved and reach the market in more than a decade, but its ...

3. Does The VIVUS, Inc. (NASDAQ:VVUS) Share Price Fall ... - AOL

   www.aol.com/news/does-vivus-inc-nasdaq-vvus...

   For premium support please call: 800-290-4726 more ways to reach us

4. VVUS: New Ideas for Established Portfolio

   www.aol.com/news/vvus-ideas-established...

   We are initiating coverage of VIVUS, Inc. (VVUS) with a $10.00 price target based on our revenue forecasts for approved products. In addition to a portfolio of weight loss, exocrine pancreatic ...

5. 3 Reasons to Sell: VIVUS - AOL

   www.aol.com/news/2012-08-22-3-reasons-to-sell...

   For premium support please call: 800-290-4726 more ways to reach us

6. Buy, Sell, or Hold: VIVUS

   www.aol.com/2012/06/12/buy-sell-or-hold-vivus

   For premium support please call: 800-290-4726 more ways to reach us

7. Why VIVUS Shares Soared - AOL

   www.aol.com/news/2012-10-08-why-vivus-shares...

   For premium support please call: 800-290-4726 more ways to reach us

8. Hefty Profits in Store for Obesity-Drug Makers - AOL

   www.aol.com/2012/02/29/hefty-profits-in-store...

   For premium support please call: 800-290-4726 more ways to reach us

9. Weight-Loss-Drug Maker Vivus Soars on FDA Panel Review - AOL

   www.aol.com/2010/07/13/vivus-stock-fda-review...

   Vivus (VVUS) shares are trading around 15% higher Tuesday after U.S. Food and Drug Administration reviewers said its weight-loss drug Qnexa indeed helps reduce weight. Shares of rivals Orexigen ...